Generate Biomedicines Inc. (GENB)
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GENB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.74B
- EPS (TTM)
- -$2.40
- Dividend yield
- None
- 52-week range
- 11.00 – 22.67
- Day range
- 13.35 – 13.99
- Volume / Avg
- 926.22K / 1.04M
- Beta
- —
- Shares outstanding
- 128.35M
- Next earnings
- Nov 5, 2026
52-week range
GENB stock today
On Oct 7, GENB ended the session at $13.57, shedding $0.23 (1.67%), versus the S&P 500's 0.22% decline. At this level, GENB sits in the middle of its 52-week range of $11.00 to $22.67: 40.1% below the high, set on Aug 25, 2026 and 23.4% above the low. Generate Biomedicines has posted a net loss over the last twelve months (EPS of -$2.40), so its P/E ratio is not meaningful.
Generate Biomedicines's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Generate Biomedicines
Company profileGenerate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael T. Nally M.B.A.
- Headquarters
- Somerville, MA
- Employees
- 312
- IPO year
- 2026
- Website
- generatebiomedicines.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$27.00+98.97%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.50
Generate Biomedicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs GENB |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs GENB |
| NUVBNuvation Bio Inc. Class A | 4.86 | -0.41% | $1.71B | vs GENB |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs GENB |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs GENB |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs GENB |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs GENB |
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs GENB |
Indexes, lists and sector
Generate Biomedicines stock FAQ
What is Generate Biomedicines's stock price today?
GENB last traded at $13.57 as of Oct 7, 4:00 PM EDT, down 1.67% on the day. Prices are delayed at least 15 minutes.
When is Generate Biomedicines's next earnings date?
Generate Biomedicines is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.50.
Who is Generate Biomedicines's CEO?
Mr. Michael T. Nally M.B.A. is the chief executive officer of Generate Biomedicines Inc., which has about 312 employees.
What is the GENB 52-week high?
The 52-week high for GENB is $22.67 and the 52-week low is $11.00. The stock is currently 40.1% below its high.